|

Pasritamig Clinical Trials

3 actively recruiting trials across 3 locations

Also known as: JNJ-78278343

Pipeline

Phase 1: 1Phase 3: 2

Top Sponsors

  • Janssen Research & Development, LLC3

Indications

  • Cancer3
  • Metastatic Castration-resistant Prostate Neoplasms1
  • Prostatic Neoplasms, Castration-Resistant1
  • Prostatic Neoplasms1

Little Rock, Arkansas1 trial

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

Arkansas Urology

Phase 3

Aurora, Colorado1 trial

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

Rocky Mountain Cancer Centers

Phase 3

Sarasota, Florida1 trial

A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer

Florida Cancer Specialists

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.